Atossa Therapeutics Publishes KARISMA Endoxifen Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Atossa Therapeutics announced the publication of results from the KARISMA Endoxifen trial in the Journal of the National Cancer Institute. The Phase 2 study evaluated daily oral Endoxifen and demonstrated that low-dose Endoxifen significantly reduced MBD, a key risk factor for breast cancer. The article highlighted data from a study funded by Atossa. The study evaluated placebo, 1 mg, and 2 mg Endoxifen administered daily for six months in 240 healthy premenopausal women enrolled through the Swedish national mammography screening program. Elevated MBD is an established risk factor for breast cancer and a recognized pharmacodynamic marker of response to endocrine risk-reduction therapy. In the KARISMA Endoxifen trial, both the 1 mg and 2 mg Endoxifen dose levels produced statistically significant reductions in MBD compared with placebo. The 1 mg dose reduced MBD by 19.3% vs. placebo, while the 2 mg dose reduced MBD by 26.5% vs. placebo. These reductions were comparable to those previously reported with standard-dose tamoxifen, but were achieved using direct administration of Endoxifen, the most therapeutically active metabolite of tamoxifen. Both levels demonstrated a favorable tolerability profile. Adverse events were generally vasomotor in nature, consistent with those previously reported for tamoxifen.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATOS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATOS
Wall Street analysts forecast ATOS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.985
Low
7.00
Averages
18.33
High
40.00
Current: 1.985
Low
7.00
Averages
18.33
High
40.00
About ATOS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atossa Therapeutics Closes Direct Offering Raising $4.5 Million
- Funding Amount: Atossa Therapeutics has completed a registered direct offering of 1,363,637 shares, raising an initial $4.5 million, reflecting the company's appeal in capital markets despite facing market volatility challenges.
- Potential Revenue: The exercise of the Series Warrants could yield an additional $12 million, providing crucial funding for clinical development and operations, thereby supporting its innovative drug development in oncology.
- Warrant Details: The Series A warrants expire 5.5 years post-issuance, while the short-term Series B warrants expire within 2 years, offering investors diverse options and ensuring future liquidity for the company.
- Usage Plan: The company intends to utilize the proceeds for clinical development of product candidates, working capital, and general corporate purposes, a strategy that will help accelerate drug development in areas of high unmet clinical need.
See More
Atossa Therapeutics Closes Direct Offering Raising $4.5 Million
- Funding Amount: Atossa Therapeutics has completed a registered direct offering of 1,363,637 shares, raising approximately $4.5 million initially, with potential additional proceeds of $12 million if all warrants are exercised, which will significantly support the company's clinical development and operational needs.
- Warrant Details: The offering includes Series A and Series B warrants, with Series A expiring in 5.5 years and Series B in 2 years, providing a flexible financing structure that may enhance the company's future capital operations.
- Use of Proceeds: Atossa intends to utilize the net proceeds from this offering for clinical development of its product candidates, working capital, and general corporate purposes, which will help accelerate its innovative drug development in oncology.
- Market Reaction: While this financing provides short-term funding support, the uncertainty surrounding the exercise of the warrants may impact future cash inflows and shareholder confidence.
See More
Atossa Therapeutics Secures $16.5 Million Securities Purchase Agreement
- Financing Agreement: Atossa Therapeutics has entered into a securities purchase agreement with institutional investors to raise up to $16.5 million, including an initial $4.5 million investment, with an additional $12 million contingent on the full exercise of accompanying warrants, indicating a proactive approach to financing.
- Warrant Details: Investors will acquire approximately 1.36 million shares of common stock along with Series A and short-term Series B warrants, where Series A warrants can be exercised six months post-issuance and are valid for 5.5 years, while Series B warrants expire two years after issuance, providing flexibility for future capital operations.
- Planned Use of Funds: Atossa intends to utilize the net proceeds for clinical development of its oncology product candidates, working capital, and general corporate purposes, reflecting the company's strategic focus on R&D and operational needs to advance its product pipeline.
- Stock Performance Decline: Following a 1-for-15 reverse stock split, Atossa's current trading price is $2.55, down 42.09%, indicating market caution regarding its financing and future growth prospects.
See More
Atossa Therapeutics Announces Direct Offering for $16.5M
- Offering Size: Atossa Therapeutics announced a registered direct offering with institutional investors for 1.36 million shares and warrants for 2.73 million shares, with potential gross proceeds of $16.5 million, reflecting market confidence in its future growth.
- Warrant Details: The Series A and Series B warrants become exercisable after six months and expire in 5.5 years and two years, respectively, providing flexible investment options that could enhance the company's liquidity.
- Use of Proceeds: The company plans to utilize the net proceeds for clinical development, working capital, and general corporate purposes, indicating a strong focus on future R&D and market expansion to enhance its competitiveness in breast cancer drug development.
- Transaction Arrangement: Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering, which is expected to close on or about June 12, 2026, further strengthening the company's professional support in capital markets.
See More
Atossa Therapeutics Secures $4.5 Million Financing with Potential for $12 Million
- Financing Agreement: Atossa Therapeutics has entered into a securities purchase agreement with institutional investors to raise $4.5 million by selling 1,363,638 shares of common stock, reflecting market confidence in its clinical-stage drug development.
- Exercisable Warrants: The financing includes Series A and Series B warrants to purchase the same number of shares, which could potentially generate an additional $12 million if fully exercised, thereby enhancing the company's liquidity.
- Clear Use of Funds: The company intends to utilize the proceeds for clinical development of its product candidates, working capital, and general corporate purposes, indicating a strong focus on future R&D and strategic positioning.
- Compliance and Transparency: This financing adheres to SEC registration statements, ensuring that investors receive necessary investment information, which enhances the company's transparency and compliance in the capital markets.
See More
Atossa Presents New Data Highlighting (Z)-Endoxifen's Potential in Breast Cancer
- Clinical Data Presentation: Atossa Therapeutics announced that two abstracts accepted for the 2026 American Society of Clinical Oncology Annual Meeting highlight the significant estrogen receptor inhibition of (Z)-endoxifen in ER+ breast cancer, potentially providing new treatment options.
- Preclinical Research Findings: New data demonstrate that (Z)-endoxifen achieves robust estrogen receptor inhibition across clinically relevant ESR1 mutations, which commonly lead to endocrine therapy resistance, indicating the drug's potential for patients with limited treatment options.
- EVANGELINE Trial Progress: The ongoing EVANGELINE study evaluates the effects of (Z)-endoxifen combined with goserelin as neoadjuvant therapy for ER+/HER2- premenopausal women, aiming to improve clinical response and safety outcomes.
- Broad Market Potential: Atossa's (Z)-endoxifen program is supported by a growing global intellectual property portfolio, showcasing its extensive application potential in oncology and rare diseases, which may lead to significant market growth opportunities for the company.
See More
Atossa Therapeutics Closes Direct Offering Raising $4.5 Million
- Funding Amount: Atossa Therapeutics has completed a registered direct offering of 1,363,637 shares, raising an initial $4.5 million, reflecting the company's appeal in capital markets despite facing market volatility challenges.
- Potential Revenue: The exercise of the Series Warrants could yield an additional $12 million, providing crucial funding for clinical development and operations, thereby supporting its innovative drug development in oncology.
- Warrant Details: The Series A warrants expire 5.5 years post-issuance, while the short-term Series B warrants expire within 2 years, offering investors diverse options and ensuring future liquidity for the company.
- Usage Plan: The company intends to utilize the proceeds for clinical development of product candidates, working capital, and general corporate purposes, a strategy that will help accelerate drug development in areas of high unmet clinical need.
See More
Atossa Therapeutics Closes Direct Offering Raising $4.5 Million
- Funding Amount: Atossa Therapeutics has completed a registered direct offering of 1,363,637 shares, raising approximately $4.5 million initially, with potential additional proceeds of $12 million if all warrants are exercised, which will significantly support the company's clinical development and operational needs.
- Warrant Details: The offering includes Series A and Series B warrants, with Series A expiring in 5.5 years and Series B in 2 years, providing a flexible financing structure that may enhance the company's future capital operations.
- Use of Proceeds: Atossa intends to utilize the net proceeds from this offering for clinical development of its product candidates, working capital, and general corporate purposes, which will help accelerate its innovative drug development in oncology.
- Market Reaction: While this financing provides short-term funding support, the uncertainty surrounding the exercise of the warrants may impact future cash inflows and shareholder confidence.
See More
Atossa Therapeutics Secures $16.5 Million Securities Purchase Agreement
- Financing Agreement: Atossa Therapeutics has entered into a securities purchase agreement with institutional investors to raise up to $16.5 million, including an initial $4.5 million investment, with an additional $12 million contingent on the full exercise of accompanying warrants, indicating a proactive approach to financing.
- Warrant Details: Investors will acquire approximately 1.36 million shares of common stock along with Series A and short-term Series B warrants, where Series A warrants can be exercised six months post-issuance and are valid for 5.5 years, while Series B warrants expire two years after issuance, providing flexibility for future capital operations.
- Planned Use of Funds: Atossa intends to utilize the net proceeds for clinical development of its oncology product candidates, working capital, and general corporate purposes, reflecting the company's strategic focus on R&D and operational needs to advance its product pipeline.
- Stock Performance Decline: Following a 1-for-15 reverse stock split, Atossa's current trading price is $2.55, down 42.09%, indicating market caution regarding its financing and future growth prospects.
See More
Atossa Therapeutics Announces Direct Offering for $16.5M
- Offering Size: Atossa Therapeutics announced a registered direct offering with institutional investors for 1.36 million shares and warrants for 2.73 million shares, with potential gross proceeds of $16.5 million, reflecting market confidence in its future growth.
- Warrant Details: The Series A and Series B warrants become exercisable after six months and expire in 5.5 years and two years, respectively, providing flexible investment options that could enhance the company's liquidity.
- Use of Proceeds: The company plans to utilize the net proceeds for clinical development, working capital, and general corporate purposes, indicating a strong focus on future R&D and market expansion to enhance its competitiveness in breast cancer drug development.
- Transaction Arrangement: Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering, which is expected to close on or about June 12, 2026, further strengthening the company's professional support in capital markets.
See More
Atossa Therapeutics Secures $4.5 Million Financing with Potential for $12 Million
- Financing Agreement: Atossa Therapeutics has entered into a securities purchase agreement with institutional investors to raise $4.5 million by selling 1,363,638 shares of common stock, reflecting market confidence in its clinical-stage drug development.
- Exercisable Warrants: The financing includes Series A and Series B warrants to purchase the same number of shares, which could potentially generate an additional $12 million if fully exercised, thereby enhancing the company's liquidity.
- Clear Use of Funds: The company intends to utilize the proceeds for clinical development of its product candidates, working capital, and general corporate purposes, indicating a strong focus on future R&D and strategic positioning.
- Compliance and Transparency: This financing adheres to SEC registration statements, ensuring that investors receive necessary investment information, which enhances the company's transparency and compliance in the capital markets.
See More
Atossa Presents New Data Highlighting (Z)-Endoxifen's Potential in Breast Cancer
- Clinical Data Presentation: Atossa Therapeutics announced that two abstracts accepted for the 2026 American Society of Clinical Oncology Annual Meeting highlight the significant estrogen receptor inhibition of (Z)-endoxifen in ER+ breast cancer, potentially providing new treatment options.
- Preclinical Research Findings: New data demonstrate that (Z)-endoxifen achieves robust estrogen receptor inhibition across clinically relevant ESR1 mutations, which commonly lead to endocrine therapy resistance, indicating the drug's potential for patients with limited treatment options.
- EVANGELINE Trial Progress: The ongoing EVANGELINE study evaluates the effects of (Z)-endoxifen combined with goserelin as neoadjuvant therapy for ER+/HER2- premenopausal women, aiming to improve clinical response and safety outcomes.
- Broad Market Potential: Atossa's (Z)-endoxifen program is supported by a growing global intellectual property portfolio, showcasing its extensive application potential in oncology and rare diseases, which may lead to significant market growth opportunities for the company.
See More
